News Center

News Center

Shengshi Taikang's Yu Qiang: The innovative drug industry is a "Long March"—if you give up halfway, you lose.

Shengshi Taikang's Yu Qiang: The innovative drug industry is a "Long March"—if you give up halfway, you lose.

In 2020, the healthcare sector bucked the trend and surged ahead, sparking a "gold rush" in the capital markets. In terms of funding volume, healthcare companies raised at least nearly 200 billion yuan in the primary market during the first three quarters of this year—amounting to almost as much as Beijing’s total tax revenue for the entire first half of the year. As for growth speed, many companies saw their valuations skyrocket by multiples within just one year. “Recently, a reporter came to interview me, and I joked, ‘Right now, the sky above Suzhou smells like money,’” said Dr. Yu Qiang, founder of Shengshi Taike and a participant in the “Elite Leadership Development and Empowerment Program,” organized by the Enterprise Development Service Center of Suzhou Industrial Park and hosted by the Academy.

Time：2020-11-13 17:13

"Guangming Daily," Front Page – A Report Card from Open Innovation

"Guangming Daily," Front Page – A Report Card from Open Innovation

Located in eastern Jiangsu Province, Suzhou Industrial Park spans 278 square kilometers—every inch of this land brimming with immense potential and dynamic energy. Despite the significant impact of the COVID-19 pandemic, the park achieved a regional GDP of over 129 billion yuan in the first half of the year, representing a robust 2.1% year-on-year growth. Meanwhile, total import and export value surged to more than 305.2 billion yuan, up by 4.5%; registered foreign investment reached $2.07 billion, while actual utilized foreign capital hit $1.28 billion—surging by 149% and 196%, respectively. These impressive results are nothing short of remarkable. But what makes Suzhou Industrial Park stand out? The answer is both simple and profound: **openness and innovation.** As the primary hub for openness and innovation in Suzhou, the park has consistently maintained a forward-leaning, pioneering spirit. It fearlessly pushes boundaries, seizes opportunities with precision, and ultimately places open innovation at the heart of its strategy. This approach may very well be the "secret formula" that keeps the park thriving—even amid complex and ever-changing global circumstances—and it’s undoubtedly its most powerful "trump card."

Time：2020-08-14 09:16

Shengshi Taikang: The Molecular Designer and Their Business Vision

Shengshi Taikang: The Molecular Designer and Their Business Vision

In 2006, Merck’s sitagliptin was officially launched for diabetes treatment, becoming the world’s first approved DPP4 inhibitor. At the time, Yu Qiang, co-founder and CEO of Shengshi Taikang, was running a U.S.-based company focused on applying fragment-based drug discovery technology to deliver drug precursor compounds. After sitagliptin hit the market, Yu Qiang noticed that the compound still had room for improvement in terms of its fit with the target enzyme DPP4. Driven by this insight, his company synthesized numerous compounds targeting the same DPP4 pathway—and subsequently compared them against the publicly available data on sitagliptin. Ultimately, these new compounds demonstrated comparable efficacy to sitagliptin, prompting Yu Qiang to realize that this approach might be heading in the right direction, offering clear opportunities for further optimization.

Time：2020-07-20 09:21

Shengshi Taikе partners with Yunxuan Pharmaceutical to broadly deploy CXCR4 antagonists.

Shengshi Taikе partners with Yunxuan Pharmaceutical to broadly deploy CXCR4 antagonists.

Recently, Shengshi Taikang, which focuses on both internal R&D and strategic external collaborations, announced that it has signed an exclusive cooperation and licensing agreement with Yunxuan Pharmaceutical, securing global exclusive rights for the development and commercialization of a preclinical-stage CXCR4 antagonist—a promising compound targeting chemokine receptor type 4.

Time：2020-04-16 17:16

Shengshi Taikang: Tafamidis Marketing Application Accepted by NMPA

Shengshi Taikang: Tafamidis Marketing Application Accepted by NMPA

Every year, the last day of February marks "International Rare Disease Day." Today, more than 7,000 rare diseases are known worldwide, with 80% having genetic origins. Yet only a few dozen of these conditions can currently be effectively treated or managed with medication. Diagnosing rare diseases remains challenging, and the cost of life-saving treatments is often prohibitively high, leaving patients struggling to survive. At the forefront of rare disease research and development, Shengshi Taikang is dedicated to delivering cutting-edge therapeutic solutions that offer new hope to those battling these debilitating conditions. On this special day, Shengshi Taikang proudly announces that its pioneering oral drug, teriflunomide—developed specifically for treating multiple sclerosis (MS), a rare and chronic autoimmune disorder—has officially received acceptance from China’s National Medical Products Administration for its marketing application.

Time：2020-02-29 08:54

Shengshi Taikang: The first domestically developed, original DPP-4 inhibitor, Sitagliptin, advances from "Phase 2 to Phase 3" without delay.

Shengshi Taikang: The first domestically developed, original DPP-4 inhibitor, Sitagliptin, advances from "Phase 2 to Phase 3" without delay.

Shengshi Taikang Biopharmaceutical Technology (Suzhou) Co., Ltd. is an innovative technology company dedicated to the research and development of antidiabetic drugs. The company’s newly developed phosphate senvogliflozin tablets are a novel DPP-4 inhibitor, boasting high potency and exceptional safety profiles. Notably, the drug was successfully selected twice—in 2012 and 2018—for China’s national key programs focused on the creation of major new medicines during the 12th and 13th Five-Year Plans, respectively. This year, data from a large-scale Phase I clinical trial have demonstrated that, compared to the positive-control drug sitagliptin, Shengshi Taikang’s phosphate senvogliflozin shows promising efficacy and remains safe and reliable for treating type 2 diabetes. Currently, the drug has received official approval from the National Medical Products Administration’s Center for Drug Evaluation, allowing it to skip Phase II clinical trials and proceed directly into Phase III testing.

Time：2019-11-14 17:17

[Ranking] Cyzone 2019 Top 50 Innovative Healthcare and Wellness Companies in China Unveiled—Growing and Innovating Against the Grain Amidst the Capital Winter

[Ranking] Cyzone 2019 Top 50 Innovative Healthcare and Wellness Companies in China Unveiled—Growing and Innovating Against the Grain Amidst the Capital Winter

“The valuation bubble in the healthcare and wellness sector is gradually being deflated, as the market returns to rationality.” When asked about the biggest shift in China’s healthcare and wellness venture capital landscape in recent years, several investors highlighted this very point. They noted that after the investment and IPO boom in the healthcare and wellness industry from 2015 to 2017, the sector is now entering a major reshuffling phase. Both startups and investment firms alike will face a process of survival of the fittest, with the Matthew effect intensifying. Ultimately, only the leading companies and institutions will thrive—and even grow stronger over time.

Time：2019-09-19 09:39

What makes the promising new diabetes drug, senglutide—poised to become the best-in-class—so exceptional?

What makes the promising new diabetes drug, senglutide—poised to become the best-in-class—so exceptional?

Last month, Shengshi Taikang Biopharmaceutical Technology (Suzhou) Co., Ltd. announced the completion of its Pre-A round of financing, revealing that its flagship product, Shengetlin, is poised to become a best-in-class drug in its category. Shengetlin is a novel antidiabetic medication belonging to the class of DPP-4 inhibitors—glucagon-like peptide-1 (GLP-1) receptor agonists. Since Merck introduced sitagliptin, the world’s first DPP-4 inhibitor, to the U.S. market in 2006, DPP-4 has rapidly emerged as one of the most promising targets in diabetes drug development. Over the past few years, several top-10 global pharmaceutical companies have successfully developed multiple next-generation DPP-4 inhibitors, each offering improved efficacy, formulation options, and reduced side effects compared to sitagliptin.

Time：2019-08-23 09:53

< 1...78910 >
中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地